Your browser doesn't support javascript.
loading
Auriculotherapy in prevention of migraine attacks: an open randomized trial.
Michel-Cherqui, Mireille; Ma, Sabrina; d'Ussel, Marguerite; Ebbo, David; Spassova, Antoinette; Chaix-Couturier, Carine; Szekely, Barbara; Fischler, Marc; Lemaire, Nicolas; Le Guen, Morgan.
Afiliación
  • Michel-Cherqui M; Department of Anesthesiology, Hospital Foch, Suresnes, France.
  • Ma S; Department of Medicine, Université Versailles Saint-Quentin en Yvelines, Versailles, France.
  • d'Ussel M; Department of Anesthesiology, Hospital Foch, Suresnes, France.
  • Ebbo D; Department of Medicine, Université Versailles Saint-Quentin en Yvelines, Versailles, France.
  • Spassova A; Department of Pain Medicine, Hospital Saint Joseph, Paris, France.
  • Chaix-Couturier C; Department of Pain Medicine, Hospital Saint Joseph, Paris, France.
  • Szekely B; General Practice, Maison-Alfort, France.
  • Fischler M; General Practice, Montigny le Bretonneux, France.
  • Lemaire N; Department of Anesthesiology, Hospital Foch, Suresnes, France.
  • Le Guen M; Department of Medicine, Université Versailles Saint-Quentin en Yvelines, Versailles, France.
Front Neurol ; 14: 1193752, 2023.
Article en En | MEDLINE | ID: mdl-37284181
ABSTRACT
Use of auriculotherapy to prevent episodic migraine pain has seldom been reported. The aim of this open study was to show that three sessions of auriculotherapy, 1 month apart, using semi-permanent needles decrease frequency and intensity of an attack in patients presenting episodic migraine. A total of 90 patients were randomized to the treatment group (AUR group, n = 58) or the control group (C group, n = 32). Four patients dropped out during the study (three in the AUR group and one in the C group). The number of days with migraine and non-migraine headache was similar when the analysis focused on the 3 months of the study or on the difference in each group of this number between the 3 months preceding the inclusion and the 3 months of the study (p = 0.123). AUR group patients had fewer days with non-migraine headache (p = 0.011) and took less Triptans (p = 0.045) than group C. Number of days with migraine, sum of the pain intensities of all migraines and non-migraine headaches, and total number of analgesics taken, other than triptan, were similar between groups. MIDAS score decreased with time in the AUR group while it increased in the C group whether in absolute values (p = 0.035) or as categories (p = 0.037). These contrasted results should lead to further study of the effectiveness of auriculotherapy for the prevention of migraine. Clinical trail registration Protocol registered on the Clinicaltrials.gov, website (January 30, 2017, NCT03036761).
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Front Neurol Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Front Neurol Año: 2023 Tipo del documento: Article País de afiliación: Francia